Wei S J, Chang R L, Hennig E, Cui X X, Merkler K A, Wong C Q, Yagi H, Jerina D M, Conney A H
Department of Chemical Biology and Pharmacognosy, College of Pharmacy, Rutgers, State University of New Jersey, Piscataway 08855.
Carcinogenesis. 1994 Aug;15(8):1729-35. doi: 10.1093/carcin/15.8.1729.
Earlier studies from our laboratories characterized the mutation profile of the optically active (+)-7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene [(+)-BPDE--the ultimate carcinogenic metabolite of benzo[a]pyrene] in the coding region of the hypoxanthine (guanine) phosphoribosyltransferase (HPRT) gene of Chinese hamster V-79 cells. In the present study, we evaluated the mutation profile of (-)-7S,8R-dihydroxy-9R, 10S-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene [(-)-BPDE-a weakly carcinogenic or inactive enantiomer] and compared its mutation profile with that of (+)-BPDE. In both diol epoxide enantiomers, the benzylic 7-hydroxy group and epoxide oxygen are trans. The mutation frequency for V-79 cells treated with DMSO vehicle or with a low, non-cytotoxic dose (0.5 microM) or a high cytotoxic dose (2.0 microM) of (-)-BPDE was 1, 25 or 185 8-azaguanine-resistant colonies/10(5) survivors, respectively. Independent 8-azaguanine-resistant clones were isolated, and complementary DNAs were prepared by reverse transcription. The coding region of the HPRT gene was amplified by the polymerase chain reaction and sequenced. Altogether, 92 (-)-BPDE-induced mutant clones were examined. At both doses, base substitutions were the most prevalent mutations observed (present in approximately 7% of the mutant clones), followed by exon deletions (present in approximately 22% of the mutant clones) and frame shift mutations (present in approximately 6% of the mutant clones) in the cDNAs analyzed. At the high cytotoxic dose, 5 out of 36 base substitutions occurred at AT base pairs (14%) and 31 at GC base pairs (86%). At the low, non-cytotoxic dose, 7 out of 34 base substitutions were at AT base pairs (21%) and 27 were at GC base pairs (79%). Although there was a trend towards an increase in the proportion of mutations at AT base pairs when the dose of (-)-BPDE was decreased, this trend was not statistically significant. The data also indicated no dose-dependent differences in the kinds of base substitutions or exon deletions in cDNAs induced by (-)-BPDE. Ninety-one per cent of the (-)-BPDE-induced mutations that occurred at guanine were on the non-transcribed strand of DNA and 9% were on the transcribed strand. In contrast to these results, 50% of the (-)-BPDE-induced mutations that occurred at adenine were on the transcribed strand and 50% on the non-transcribed strand.(ABSTRACT TRUNCATED AT 400 WORDS)
我们实验室早期的研究对中国仓鼠V - 79细胞次黄嘌呤(鸟嘌呤)磷酸核糖基转移酶(HPRT)基因编码区中具有光学活性的(+)-7R,8S - 二羟基 - 9S,10R - 环氧 - 7,8,9,10 - 四氢苯并[a]芘[(+)-BPDE——苯并[a]芘的最终致癌代谢物]的突变谱进行了表征。在本研究中,我们评估了(-)-7S,8R - 二羟基 - 9R,10S - 环氧 - 7,8,9,10 - 四氢苯并[a]芘[(-)-BPDE——一种弱致癌或无活性的对映体]的突变谱,并将其与(+)-BPDE的突变谱进行了比较。在这两种二醇环氧化物对映体中,苄基7 - 羟基和环氧氧是反式的。用二甲基亚砜载体或低的、无细胞毒性剂量(0.5微摩尔)或高细胞毒性剂量(2.0微摩尔)的(-)-BPDE处理的V - 79细胞的突变频率分别为1、25或185个8 - 氮杂鸟嘌呤抗性集落/10⁵个存活细胞。分离出独立的8 - 氮杂鸟嘌呤抗性克隆,并通过逆转录制备互补DNA。HPRT基因的编码区通过聚合酶链反应扩增并测序。总共检查了92个(-)-BPDE诱导的突变克隆。在两种剂量下,碱基替换是观察到的最普遍的突变(约占突变克隆的7%),其次是外显子缺失(约占突变克隆的22%)和移码突变(约占分析的cDNA突变克隆的6%)。在高细胞毒性剂量下,36个碱基替换中有5个发生在AT碱基对(14%),31个发生在GC碱基对(86%)。在低的、无细胞毒性剂量下,34个碱基替换中有7个在AT碱基对(21%),27个在GC碱基对(79%)。尽管当(-)-BPDE剂量降低时,AT碱基对处突变比例有增加的趋势,但这种趋势无统计学意义。数据还表明,(-)-BPDE诱导的cDNA中碱基替换或外显子缺失的种类没有剂量依赖性差异。在鸟嘌呤处发生的(-)-BPDE诱导的突变中,91%位于DNA的非转录链上,9%位于转录链上。与这些结果相反,在腺嘌呤处发生的(-)-BPDE诱导的突变中,50%位于转录链上,50%位于非转录链上。(摘要截断于400字)